Defiance ETFs’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Defiance ETFs's REGN Position: Q2 2026 in Review
Defiance ETFs increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $26.5K and bringing the position to 394 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #356.
Defiance ETFs first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $274K in Q1 2026. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Defiance ETFs held 394 shares of Regeneron Pharmaceuticals worth $246K as of Q2 2026.
- Defiance ETFs bought 39 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $26.5K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Defiance ETFs's portfolio in Q2 2026, its #356 holding.
- Defiance ETFs first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- Defiance ETFs's Regeneron Pharmaceuticals position peaked at $274K in Q1 2026.
- 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.